Used in pharmaceutical research as a potent and selective agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is primarily investigated for the treatment of type 2 diabetes due to its ability to enhance glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. The compound also promotes satiety and reduces food intake, making it a candidate for obesity management. Its structure allows for improved metabolic stability and prolonged in vivo activity, supporting development as a long-acting injectable or oral antidiabetic agent. Currently, it serves as a lead compound in optimizing next-generation therapies for metabolic disorders.